AbbVie has completed the acquisition of ImmunoGen for $10.1bn, a move that significantly bolsters its oncology pipeline with promising treatments for solid tumours and haematologic malignancies.

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

关于ELAHERE ELAHERE为中美华东与ImmunoGen, Inc.（目前已被AbbVie收购）合作开发的针对叶酸受体α（FRα，一种在卵巢癌中高表达的细胞表面蛋白）靶点的 ...

华东医药公告，全资子公司中美华东与美国ImmunoGen, Inc.达成独家临床开发及商业化协议。华东医药获得 ImmunoGen美国临床三期在研产品Mirvetuximab Soravtansine（新型抗体偶联药物 ADC，用于治疗卵巢癌）在大中华区的独家临床开发及商业化权益。中美华东将向ImmunoGen ...

You will be redirected to our submission process. Vaccines are the most efficient way of preventing viral infections. On an individual level, vaccines prevent disease and on a population level, ...

Learn more about Christopher Missling, PhD, on LinkedIn and explore the innovative work of Anavex Life Sciences at their website. In the relentless pursuit of solutions for neurodegenerative diseases ...

ImmunoGen公司简介。此公司档案包括ImmunoGen(IMGN)公司所处行业，业务概况，地址，联系方式，官网和高管档案资料。 ImmunoGen Inc是一家商业阶段的生物技术公司。该公司专注于抗体药物偶联物(ADC)的开发和商业化，以改善癌症患者的预后。采用该公司技术的ADC包含一 ...